Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F24%3A00080660" target="_blank" >RIV/00209805:_____/24:00080660 - isvavai.cz</a>
Result on the web
<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12836508/" target="_blank" >https://pmc.ncbi.nlm.nih.gov/articles/PMC12836508/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.esmogo.2024.100074" target="_blank" >10.1016/j.esmogo.2024.100074</a>
Alternative languages
Result language
angličtina
Original language name
Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
Original language description
Background: Precision oncology is gaining momentum in managing patients with gastrointestinal cancers. This study examines the implementation of personalized medicine technologies in upper gastrointestinal (UGI) oncology across European academic centers. Material and methods: Forty-five oncology specialists from 41 European institutions completed a survey designed by the Personalized Medicine Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Working Group, providing insights into molecular testing, timing, availability of targeted therapies, funding sources, and utilization of molecular tumor boards (MTBs) for patients with UGI cancers. Frequencies and percentages were calculated. Results: Routine testing for human epidermal growth factor receptor 2 (HER2, 100%), programmed death-ligand 1 (PD-L1, 89%), and DNA mismatch repair (MMR, 91%) is implemented in most centers. Comprehensive gene panels on tumor tissue are frequently utilized, especially in biliary tract cancer, with almost all centers incorporating them into routine practice. Blood-based sequencing is increasingly employed, and half of centers carry out comprehensive gene panels for circulating tumor DNA analyses. MTBs are regularly held in 76% of centers, predominantly utilizing ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)-based recommendations for tissue molecular alterations. The translation of genomic information into prescribed treatments remains limited, however, with the majority of centers reporting w25% of molecularly stratified treatment decisions following comprehensive genetic testing. Conclusion: This survey provides important insights into current personalized medicine practice in European academic clinical centers for UGI oncology. Despite widespread adoption of molecular testing and implementation of MTBs, further efforts are needed to optimize the integration of personalized medicine into clinical practice.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ESMO Gastrointestinal Oncology
ISSN
—
e-ISSN
2949-8198
Volume of the periodical
5
Issue of the periodical within the volume
September 2024
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
9
Pages from-to
100074
UT code for WoS article
001634490400001
EID of the result in the Scopus database
2-s2.0-105011045983